Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Operating Cash Flow To Debt?

  Amgen Inc ( AMGN ) |
1989 - 2021 (33 years)

Operating Cash Flow To Debt is 
0.65 (1Y +9.49% )

AMGN Stock Price & Operating Cash Flow To Debt

Operating Cash Flow To Debt for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Operating Cash Flow To Debt

chevron_right 2021 0.71 +1.4x
( +2.7% / year avg)
chevron_left 1989 0.3
vertical_align_top Peak 0.71 +5.83x
vertical_align_bottom Bottom 0.1
arrow_drop_up # Up Years 15 15 of 33
years up.
arrow_drop_down # Down Years 18
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1989 , or +809x faster than it's operating cash flow to debt over the same period.
  • If AMGN grows it's stock at the same rate as it's operating cash flow to debt (+2.7%/year) , it's stock price will grow +130% and hit $322.08 over the next 10 years.
  • AMGN's stock price has gone up 0 of the 15 years (0%) it's operating cash flow to debt were also up.
5-Year Change 🚀
+19.8%$26.5BNet Revenue (Sales)
+49.1%$6.4BCost of Revenue (Sales)
+12.8%$20.1BGross Profit Margin
-5.86%3.04Gross Profit Margin Ratio
+12.4%$4.9BResearch and Development (R&D)
+25.2%$7.1BSelling, General, and Administrative (SG&A)
+24.5%$12.1BTotal Operating Expenses
+32.1%$18.5BCost & Expenses
+12.0%$1.3BInterest Expense/Income, Net
+61.1%$3.5BDepreciation & Amortization (D&A)
+11.9%$11.5BEBITDA
-6.63%1.74EBITDA Margin
-1.23%$8.0BOperating Income
-17.6%1.21Operating Margin
-1.88%$7.5BPretax Income (Earnings)
-18.1%1.13Pretax Income (Earnings) Margin
+131%$1.0BProvision For Income Taxes
-10.3%$6.5BNet Income (Earnings)
-25.1%0.97Net Profit Margin
+15.5%11.04Earnings Per Share (EPS)
+16.5%11.04Earnings Per Share (EPS) Diluted
-22.4%$2.3BShares Outstanding
-23.1%$2.3BShares Outstanding (Diluted)
+51.2%$25.1BCash and Cash Equivalents
-83.9%$17.5BShort Term Investments
-66.1%$42.6BCash And Short-Term Investments
+59.9%$15.6BInventory
+21.9%$8.3BOther Current Assets
-45.1%$84.6BTotal Current Assets
+42.5%$66.3BIntangible Assets
+18.3%$125.1BGoodwill and Intangible Assets
-12.1%$251.8BTotal Assets
+47.3%$5.7BAccounts Payables
-96.0%$364.0MShort-term Debt
+34.5%$46.6BTotal Current Liabilities
+12.2%$131.6BLong-term Debt
-38.3%$8.1BOther Non-Current Liabilities
+20.3%$167.5BTotal Non-Current Liabilities
+23.1%$214.2BTotal Liabilities
+3.76%$127.2BCommon Stock
+926%-$85.6BRetained Earnings
+105%-$3.9BAccumulated Other Comprehensive Income Loss
-66.5%$37.6BTotal Shareholders Equity
-12.1%$251.8BTotal Liabilities & Stockholders Equity
+4.53%$131.9BTotal Debt
-2.52%$106.9BNet Debt
-114.6%$208.0MDeferred Income Tax
+312%$1.3BStock-Based Compensation (SBC)
+76.0%-$12.9BChange in Working Capital
+235%-$1.6BAccounts Receivables
-68.2%$38.0BOther Working Capital
+161%-$1.9BOther Non-Cash Items
+4.51%$8.6BNet Cash Provided by Operating Activities
-15.6%-$692.0MInvestments in PP&E
-49.1%-$12.6BPurchase of Investments
-69.0%$8.2BSales/Maturities of Investments
-48.8%-$164.0MOther Investing Activities
+493%-$5.5BNet Cash used for Investing Activities
+1,060%-$5.8BDebt Repayment
+558%-$4.8BCommon Stock Repurchased
+56.4%-$3.7BDividends Paid
-87.0%-$12.0MOther Financing Activities
+294%-$14.4BNet Cash Used Provided by Financing Activities
-407.3%-$11.3BNet Change in Cash
+51.2%$25.1BCash at End of Period
+181%$36.3BCash at Beginning of Period
+4.51%$8.6BOperating Cash Flow
-15.6%-$692.0MCapital Expenditure (capex)
+6.74%$7.9BFree Cash Flow
  • AMGN Historical Operating Cash Flow To Debt Table

    Year Operating Cash Flow To Debt YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 0.71 14.7% - -
    4/1/2020 0.61 18.2% - -
    4/1/2019 0.52 48.2% - -
    4/1/2018 0.35 89.6% - -
    4/1/2017 0.19 -3.5% - -
    4/1/2016 0.19 -3.7% - -
    4/1/2015 0.2 -4.8% - -
    4/1/2014 0.21 -6.5% - -
    4/1/2013 0.22 2.5% - -
    4/1/2012 0.22 38.4% - -
    4/1/2011 0.16 -3.2% - -
    4/1/2010 0.16 -5.6% - -
    4/1/2009 0.17 -13.4% - -
    4/1/2008 0.2 -3.8% - -
    4/1/2007 0.21 8.7% - -
    4/1/2006 0.19 24.6% - -
    4/1/2005 0.15 19.8% - -
    4/1/2004 0.13 23.7% - -
    4/1/2003 0.1 -44.5% - -
    4/1/2002 0.19 -6.7% - -
    4/1/2001 0.2 -15.9% - -
    4/1/2000 0.24 -15.0% - -
    4/1/1999 0.28 -2.9% - -
    4/1/1998 0.29 3.3% - -
    4/1/1997 0.28 -8.0% - -
    4/1/1996 0.3 -8.2% - -
    4/1/1995 0.33 9.3% - -
    4/1/1994 0.3 -11.1% - -
    4/1/1993 0.34 -11.6% - -
    4/1/1992 0.38 -20.7% - -
    4/1/1991 0.48 47.6% - -
    4/1/1990 0.33 11.1% - -
    4/1/1989 0.3 - - -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
  • CFO to debt = Cash flow from operations / total debt


    For more detailed definitions, please see Investopedia.
    Year Operating Cash Flow To Debt YoY % Change Stock Price YoY % Change (Stock Price) total se net revenue
    4/1/2021 0.71 14.7% 37636.00 26536.00
    4/1/2020 0.61 18.2% 40776.00 24987.00
    4/1/2019 0.52 48.2% 45053.00 23395.00
    4/1/2018 0.35 89.6% 70119.00 23319.00
    4/1/2017 0.19 -3.5% 124463.00 23012.00
    4/1/2016 0.19 -3.7% 117671.00 22562.00
    4/1/2015 0.20 -4.8% 107735.00 21457.00
    4/1/2014 0.21 -6.5% 94544.00 19743.00
    4/1/2013 0.22 2.5% 80873.00 18086.00
    4/1/2012 0.22 38.4% 77044.00 16817.00
    4/1/2011 0.16 -3.2% 98095.00 15450.00
    4/1/2010 0.16 -5.6% 92247.00 15021.00
    4/1/2009 0.17 -13.4% 84571.00 14584.00
    4/1/2008 0.20 -3.8% 75321.00 14997.00
    4/1/2007 0.21 8.7% 72053.00 14861.00
    4/1/2006 0.19 24.6% 72402.00 13704.00
    4/1/2005 0.15 19.8% 78856.00 12068.00
    4/1/2004 0.13 23.7% 78179.20 9987.20
    4/1/2003 0.10 -44.5% 75191.40 7775.80
    4/1/2002 0.19 -6.7% 32712.40 4801.20
    4/1/2001 0.20 -15.9% 19090.30 3797.20
    4/1/2000 0.24 -15.0% 14329.33 3390.13
    4/1/1999 0.28 -2.9% 11288.00 3148.64
    4/1/1998 0.29 3.3% 8711.70 2502.70
    4/1/1997 0.28 -8.0% 8433.10 2335.80
    4/1/1996 0.30 -8.2% 7013.30 2120.30
    4/1/1995 0.33 9.3% 5583.20 1833.80
    4/1/1994 0.30 -11.1% 5157.40 1556.60
    4/1/1993 0.34 -11.6% 4124.40 1398.40
    4/1/1992 0.38 -20.7% 3126.00 1199.60
    4/1/1991 0.48 47.6% 1471.20 711.60
    4/1/1990 0.33 11.1% 1092.10 340.00
    4/1/1989 0.30 654.00 192.67